# Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1

> **NCT06222827** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Hospitalier Universitaire de Nice** · enrollment: 46 (actual)

## Conditions studied

- Facioscapulohumeral Muscular Dystrophy 1

## Interventions

- **DRUG:** Satralizumab Prefilled Syringe
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT06222827
- **Lead sponsor:** Centre Hospitalier Universitaire de Nice
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-24
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06222827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06222827, "Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06222827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*